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Abstract
Background: The prognosis for pancreatic cancer remains dismal because many patients are diagnosed with
unresectable cancer at the initial diagnosis. Recently, conversion surgery was reported as an effective treatment for
initially unresectable pancreatic cancer with a favorable response to non-surgical treatment lasting over 240 days.
Here, we describe a case of locally advanced pancreatic cancer (LAPC) successfully resected after treatment with
S-1 and radiation followed by gemcitabine/nab-paclitaxel therapy.
Case presentation: A 73-year-old man with LAPC was referred to our hospital. Computed tomography findings
revealed a 2.5-cm mass in the pancreatic body that had invaded the celiac artery, common hepatic artery, and
splenic artery. Superior mesenteric artery (SMA) encasement was not observed, but tumor abutment over 180° with
the main tumor was detected. Staging laparoscopy showed no findings of distant metastasis, and washing cytology
revealed no malignancy. He was diagnosed with unresectable pancreatic cancer. Treatment with S-1 with radiation
therapy followed by gemcitabine with nab-paclitaxel was performed. Six months after the initial treatment, the
tumor size had decreased to 1.2 cm, and encasement of the main artery was diminished. Though abutment to the
main artery, including the SMA, was still detected, distal pancreatectomy with celiac artery resection was performed.
The histopathological findings around the celiac artery revealed fibrous changes with an Evans classification of
grade IIb. There was no residual cancer at the periphery; thus, R0 resection was achieved. The patient has been
healthy and without recurrence for more than 12 months since the initial treatment.
Conclusions: Gemcitabine/nab-paclitaxel therapy revealed high response rate for metastasic pancreatic cancer (PC),
but the effect for LAPC proposing conversion surgery was not well discussed. In this case, we achieve R0 resection
combined with chemoradiation therapy and gemcitabine/nab-paclitaxel therapy. This regimen was also effective for
LAPC and may be used to increase the population of conversion surgery by its high response rate.
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Background
The prognosis for pancreatic cancer (PC) remains dismal
because many patients receive an initial diagnosis of
unresectable (UR) PC [1]. Among these patients, 30–
40% are considered to have locally advanced pancreatic
cancer (LAPC).
The standard treatment for LAPC has been chemo-
therapy or chemoradiation therapy [2–4]. Recently,
powerful regimens, such as FOLFIRINOX or gemcita-
bine with nab-paclitaxel, have demonstrated a high
response rate for metastatic PC [5–8]. In particular,
FOLFIRINOX has been used as a neoadjuvant treatment
for LAPC, resulting in a high conversion rate to surgical
resection by improving tumor shrinkage [9, 10]. Only
the curative treatment for PC is surgical resection; there-
fore, treatment resulting for conversion surgery was an
effective treatment strategy. The appropriate length
before surgical treatment was now controversial. Satoi
et al. revealed that surgical resection for definitively
selected patients who responded to non-surgical anti-
cancer treatment for more than 240 days could achieve
long-term survival for initially unresectable PCs [11].
However, the report did not include the recent effective
regimen such as FOLFIRINOX and Gemcitabine/Nab-
Paclitaxel.
Here, we present a case of successful achieved conver-
sion surgery for initially unresectable PC after treatment
with chemoradiotherapy followed by chemotherapy with
gemcitabine/nab-paclitaxel for under 200-day treatment
durations.
Case presentation
A 73-year-old man presented to his local hospital with a
3-month history of inappetence and body weight loss.
Abdominal ultrasonography revealed pancreatic body
cancer, and he was referred to our hospital. He had type
2 diabetes mellitus and a history of appendectomy per-
formed when he was 20 years of age. His family history
included that his uncle has a history of gastric cancer.
Laboratory data revealed a high level of hemoglobin A1c
(8.1%), but tumor markers, including carcinoembryonic
antigen (2.1 ng/mL), cancer antigen-19-9 (15.4 U/mL),
Dupan-2 (29 U/mL), and Span-1 (11.4 U/mL), were all
within normal limits. Computed tomography (CT) find-
ings revealed a 2.5-cm mass in the pancreatic body
(Fig. 1a). The celiac artery (CA), common hepatic artery
(CHA), and splenic artery (SA) showed encasement by
direct tumor invasion (Fig. 2a). There was no encase-
ment of the superior mesenteric artery (SMA), but abut-
ment of over 180° with the main tumor was seen
(Fig. 2d). Magnetic resonance cholangiopancreatography
revealed stenosis of the main pancreatic ducts with up-
stream dilatation of the pancreatic duct. Endoscopic
retrograde cholangiopancreatography imaging also dem-
onstrated pancreatic duct strictures near the pancreatic
body. Endoscopic ultrasonography-guided fine needle
aspiration cytology was performed, and pathological
findings revealed a pancreatic adenocarcinoma. Positron
emission tomography (PET) findings did not show the
possibility of distant metastasis, and the maximum
standard uptake value of the main tumor was 2.5. Sta-
ging laparoscopy showed no findings of peritoneal and/
or liver metastasis. Additionally, washing cytology did
not show malignancy. From these findings, we diagnosed
the patient with unresectable locally advanced pancreatic
cancer (UR LAPC).
Based on these findings, S-1 with radiation therapy
was performed. Five days of S-1 intake (80 mg/m2/day)
with radiation therapy (2 Gy/day) was performed per
week. This treatment continued for 5 weeks, and the
total radiation amount was 50 Gy. During this treat-
ment, the patient experienced no significant adverse ef-
fects. After chemoradiation, CT findings showed that the
encasement of the CA, CHA, and SA was released, but
abutment to the SMA was still detected (Figs. 1a and 2b, e),
so he was diagnosed as still having LAPC. Therefore,
chemotherapy with gemcitabine and nab-paclitaxel
followed.
At first, the standard regimen (i.e., days 1, 8, and 15:
injection of gemcitabine (1000 mg/m2) and nab-
paclitaxel (125 mg/m2) every 4 weeks) was proposed.
However, because grade 3 thrombocytopenia was
observed, biweekly chemotherapy was performed 12
times, and other side effects were not observed. After
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Fig. 1 Coronal computed tomography images. a Before chemoradiation. b After chemoradiation. c After gemcitabine with nab-paclitaxel therapy.
There are no significant differences in tumor volume between a and b, but c demonstrates tumor shrinkage to 1.2 cm
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the treatments, the tumor size decreased to 1.2 cm
(Fig. 1c), but abutment to the CA, CHA, SA, and SMA
was still detected (Fig. 2c, f ). PET findings did not show
the possibility of distant metastasis, and the maximum
standard uptake value for the main tumor was 2.4.
Tumor markers, including carcinoembryonic antigen
(2.9 ng/mL), cancer antigen-19-9 (12.4 U/mL), Dupan-2
(25.0 U/mL), and Span-1 (11.3 U/mL) were still all
within normal limits.
We initially proposed embolization of the CHA and
the left gastric artery before surgical treatment. However,
the CHA was too short to be coiled safely and had a risk
of embolization for the proper hepatic artery. Therefore,
we only embolized the left gastric artery, expecting in-
creased blood perfusion from the right gastric artery,
and right gastroepiploic artery to avoid acute ischemic
disease of the stomach after celiac axis resection. Six
days after blocking the left gastric artery, surgical treat-
ment was performed.
Intraoperative findings showed neither peritoneal nor
liver metastasis. Intraoperative washing cytology re-
vealed no findings of malignancy. A 2.0-cm tumor
existed at the pancreatic body. It had invaded to the
splenic vein, but far from the portal vein. Though abut-
ment to SMA was still detected around the SMA by CT
findings, intraoperative findings showed fibrous changes
around the right half of the SMA and it could be easily
separated from SMA. From these findings, we think that
two thirds resection of the nerve plexus including fi-
brous change around the SMA was enough to achieve
R0 resection. Based on these findings, we performed dis-
tal pancreatectomy with celiac axis resection with two
thirds of the nerve plexus resection around the SMA
(Fig. 3a, b). The total operation time was 438 min, and
blood loss was 1239 mL.
Histopathological findings showed that a 0.8 × 0.5 cm,
moderately differentiated tubular adenocarcinoma with
marked degeneration, was present at the pancreatic
body; 50–60% of the tumor was changed to fibrous tis-
sue, defined as grade IIb in the Evans classification
(Fig. 3c, d). The UICC TNM classification (7th edition)
was defined as T1N0M0, stage IA. Including the nerve
plexus around the SMA, there were no residual cancer
cells in the dissected margin and/or the pancreatic resec-
tion margin. Therefore, we achieved R0 resection.
After surgical treatment, there were grade B complica-
tions of the pancreatic fistula, but they were controlled
by percutaneous drainage not under general anesthesia
(Clavien-Dindo IIIa). The patient was discharged from
the hospital 52 days after surgical treatment. He has
now been treated with S-1 as adjuvant chemotherapy
and has done well without recurrence for more than
12 months from the initial treatment.
Discussion
The recommended first-line treatment for LAPC is
chemotherapy or chemoradiation therapy [2–4]. In this
case, we initially planned to administer radiation therapy
to the nerve plexus around the SMA combined with S-1
therapy, expecting a highly favorable response of the
LAPC [12, 13].However, abutment to the SMA was not
diminished after chemoradiation therapy, and the patient
was still diagnosed with UR LAPC. Thus, gemcitabine/
nab-paclitaxel therapy was selected as the second-line
a b c
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Pre treatment After S-1/ radiation therapy After G-nab therapy
Fig. 2 Axial computed tomography images showing the celiac artery, common hepatic artery, splenic artery, and superior mesenteric artery. a, d
Before chemoradiation therapy. b, e After chemoradiation therapy. c, f After gemcitabine with nab-paclitaxel therapy. a Encasement of the CA,
CHA, and SA by direct invasion of tumor (arrows). b A reduction of encasement in the CHA and SA, but abutment to the SMA is still detected
(arrows). c Suspected tumor abutment to the SMA (arrows). In f, tumor volume is decreased compared to that in d and e, but tumor abutment
to the SMA was detected in all figures (arrows)
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treatment, considering that it has a high response rate
for metastatic PC (approximately about 58.8% for Japa-
nese phase I/II cohort) expecting the down-staging of
the tumor [5]. However, after this round of chemother-
apy, tumor abutment around the SMA was still not di-
minished. In this case, the most difficult problems for
conversion surgery were to determine the effect of anti-
cancer therapy and when to perform surgical treatment.
The past literature demonstrated that it can be difficult
to evaluate local tumor progression accurately by
radiological evaluation after chemotherapy and/or
chemoradiation therapy [14]. And the other studies have
shown that tumor markers or PET findings are some-
times helpful in estimating the efficacy of anti-cancer
therapy [15, 16].However, in this case, tumor markers
were not increased and PET findings were normal before
the first-line treatment. Therefore, we could diagnose
the tumor status only based on the CT or MRI findings.
We usually decided to perform surgical treatment on
the basis of four findings: (1) the tumor itself demon-
strated relative shrinkage, (2) there were no obvious
metastatic sites, (3) tumor marker levels were all normal
range, and (4) PET findings were in the relatively lower
range. In this case, we decided the operation because
marked tumor regression was observed and maintained
for several months after chemotherapy, although the
finding around SMA was not completely diminished. An
accurate diagnosis before surgical treatment remains dif-
ficult and that the criteria for surgical resection are now
controversial. If there is a possibility for conversion
surgery, proposing surgical treatments and making a
diagnosis based on intraoperative findings are necessary
for LAPC.
Conversion surgery for LAPC was the only cure for
LAPC. A previous study recommended conversion
surgery for patients who responded to non-surgical anti-
cancer treatment for more than 240 days [11]. In that
study, most patients were treated with gemcitabine-
based regimens such as gemcitabine monotherapy or
gemcitabine/S-1 therapy. Recently, FOLFIRINOX or
gemcitabine with nab-paclitaxel therapy has shown a
high response rate for UR PC [5–8, 17]. FOLFIRINOX
has also been used as a treatment for LAPC and result-
ing in a high conversion rate to surgical resection [18].
Although gemcitabine/nab-paclitaxel therapy also dem-
onstrated a high response rate for metastatic PC [5], the
evidence for its use in LAPC is now controversial. In this
case, we successfully achieved R0 resection for UR
LAPC by using gemcitabine/nab-paclitaxel therapy after













Fig. 3 Operative and histopathological findings. a Schematic diagram of this surgical treatment. The bar shows the resection lines. b Intraoperative
image obtained after tumor resection. c, d The histopathological findings around celiac artery. About 80% of cancer cells were diminished with a
desmoplastic stroma. Arrows show residual degenerated cancer cells with perineural invasion
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suggested that this regimen was also effective for LAPC
and had the possibility to reduce the length of treatment.
In the future, this strong regimen might be proposed as
a good strategy for conversion surgery, and could result
in the increase in the number of patients who could
benefit from conversion surgery.
Conclusions
We achieved R0 resection with S-1/radiation therapy
followed by gemcitabine/nab-paclitaxel therapy. This
regimen may be used to increase the population who
could benefit from conversion surgery.
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